Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.

Verlingue L, Italiano A, Prenen H, Guerra Alia EM, Tosi D, Perets R, Lugowska I, Moiseyenko V, Gumus M, Arslan C, Lindsay CR, Deva S, Taus Á, Oaknin A, Rottey S, Cicin I, Goksu SS, Smolin A, Roselló-Keränen S, Habigt C, Marbach D, Boetsch C, Dejardin D, Sleiman N, Evers S, Richard M, Ardeshir C, Charo J, Kraxner A, Teichgräber V, Keshelava N, Dziadziuszko R

Open source

DOI: 10.1016/j.ebiom.2024.105374
Published: 2024 Nov
Container: EBioMedicine
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.ebiom.2024.105374,
  title = {Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.},
  author = {Verlingue L and Italiano A and Prenen H and Guerra Alia EM and Tosi D and Perets R and Lugowska I and Moiseyenko V and Gumus M and Arslan C and Lindsay CR and Deva S and Taus Á and Oaknin A and Rottey S and Cicin I and Goksu SS and Smolin A and Roselló-Keränen S and Habigt C and Marbach D and Boetsch C and Dejardin D and Sleiman N and Evers S and Richard M and Ardeshir C and Charo J and Kraxner A and Teichgräber V and Keshelava N and Dziadziuszko R},
  year = {2024},
  journal = {EBioMedicine},
  doi = {10.1016/j.ebiom.2024.105374},
  url = {https://doi.org/10.1016/j.ebiom.2024.105374}
}

RIS

TY  - JOUR
TI  - Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.
AU  - Verlingue L
AU  - Italiano A
AU  - Prenen H
AU  - Guerra Alia EM
AU  - Tosi D
AU  - Perets R
AU  - Lugowska I
AU  - Moiseyenko V
AU  - Gumus M
AU  - Arslan C
AU  - Lindsay CR
AU  - Deva S
AU  - Taus Á
AU  - Oaknin A
AU  - Rottey S
AU  - Cicin I
AU  - Goksu SS
AU  - Smolin A
AU  - Roselló-Keränen S
AU  - Habigt C
AU  - Marbach D
AU  - Boetsch C
AU  - Dejardin D
AU  - Sleiman N
AU  - Evers S
AU  - Richard M
AU  - Ardeshir C
AU  - Charo J
AU  - Kraxner A
AU  - Teichgräber V
AU  - Keshelava N
AU  - Dziadziuszko R
PY  - 2024
JO  - EBioMedicine
DO  - 10.1016/j.ebiom.2024.105374
UR  - https://doi.org/10.1016/j.ebiom.2024.105374
ER  -

APA

L, V., A, I., H, P., EM, G. A., D, T., R, P., I, L., V, M., M, G., C, A., CR, L., S, D., Á, T., A, O., S, R., I, C., SS, G., A, S., S, R., C, H., D, M., C, B., D, D., N, S., S, E., M, R., C, A., J, C., A, K., V, T., N, K., & R, D. (2024). Phase 2 study of the antitumour activity and safety of simlukafusp alfa (FAP-IL2v) combined with atezolizumab in patients with recurrent and/or metastatic cervical squamous cell carcinoma.. EBioMedicine. https://doi.org/10.1016/j.ebiom.2024.105374

Source records

pubmed · retrieved 2026-09-26T00:36:35.036Z